TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Hold” from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $124.1818.

A number of brokerages have recently weighed in on TMDX. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. UBS Group reduced their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Stifel Nicolaus increased their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Finally, TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research report on Tuesday, September 8th.

Insider Buying and Selling

In related news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TMDX. Candriam S.C.A. increased its position in TransMedics Group by 45.4% during the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after buying an additional 49,580 shares during the period. Emerald Investment Advisers LLC bought a new stake in TransMedics Group during the 2nd quarter worth $2,023,000. Deutsche Bank AG acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $14,415,000. Regency Capital Management Inc. DE bought a new position in TransMedics Group during the 1st quarter worth $2,172,000. Finally, Headlands Technologies LLC bought a new position in TransMedics Group during the 2nd quarter worth $1,634,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Price Performance

TransMedics Group stock opened at $85.86 on Thursday. The firm has a market capitalization of $2.97 billion, a P/E ratio of 22.07, a PEG ratio of 1.13 and a beta of 1.90. The business has a 50-day moving average of $82.29 and a 200-day moving average of $89.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the previous year, the business earned $0.92 EPS. The firm’s revenue was up 20.7% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group will post 1.46 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.